
  
    
      
        Background_NNP
        The_DT retinoic_JJ acid_NN receptors_NNS (_( RAR-α_NNP ,_, -_: β_NN ,_, and_CC -_: γ_NN )_) are_VBP
        transcription_NN factors_NNS regulating_VBG a_DT variety_NN of_IN endocrine_NN
        metabolic_JJ pathways_NNS ._. Unlike_IN anti-estrogens_JJ ,_, such_JJ as_IN
        tamoxifen_NN or_CC raloxifene_NN ,_, ligands_NNS targeted_VBN against_IN the_DT RAR_NNP
        isoforms_NNS can_MD present_VB anticancer_NN activity_NN against_IN both_DT
        estrogen_NN receptor_NN positive_JJ and_CC negative_JJ breast_NN tumor_NN cells_NNS
        [_NN 1_CD ]_NN ._. As_IN a_DT result_NN ,_, such_JJ molecules_NNS could_MD constitute_VB a_DT novel_NN
        generation_NN of_IN drugs_NNS against_IN breast_NN cancer_NN ._. For_IN reasons_NNS not_RB
        yet_RB clear_JJ ,_, both_DT agonists_NNS and_CC antagonists_NNS of_IN RAR_NNP can_MD present_VB
        anti-tumor_JJ activity_NN against_IN breast_NN ,_, prostate_NN ,_, lung_NN cancer_NN
        or_CC leukemia_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. The_DT development_NN of_IN both_DT
        types_NNS of_IN ligands_NNS could_MD therefore_RB have_VB important_JJ biomedical_JJ
        implications_NNS ._. We_PRP have_VBP recently_RB demonstrated_VBN that_IN
        antagonists_NNS could_MD be_VB discovered_VBN rationally_RB ,_, based_VBN on_IN a_DT
        model_NN of_IN the_DT antagonist-bound_JJ conformation_NN of_IN the_DT receptor_NN
        [_NN 8_CD ]_NN ._. Our_PRP$ goal_NN here_RB is_VBZ to_TO discover_VB innovative_JJ molecular_JJ
        structures_NNS with_IN RAR_NNP agonist_NN activity_NN ._.
        Several_JJ retinoid_NN and_CC non-retinoid_JJ ligands_NNS have_VBP been_VBN
        described_VBN ,_, which_WDT activate_VBP one_CD or_CC a_DT combination_NN of_IN RAR_NNP
        isoforms_NNS ._. Some_DT of_IN them_PRP ,_, such_JJ as_IN the_DT natural_JJ hormone_NN
        all-trans_JJ retinoic_JJ acid_NN (_( all-trans_JJ RA_NNP )_) (_( Fig_NNP ._. 1_LS a_DT )_) ,_, have_VBP been_VBN
        tested_VBN clinically_RB ,_, and_CC display_VB unacceptable_JJ side_NN effects_NNS ,_,
        such_JJ as_IN skin_NN dryness_NN ,_, cheilitis_NNS ,_, hypertriglyceridemia_NN and_CC
        conjunctivitis_NNS [_NN 9_CD ,_, 10_CD ]_NN ._. However_RB ,_, the_DT compounds_NNS tested_VBN so_RB
        far_RB belong_VB to_TO limited_JJ series_NN of_IN related_VBN structures_NNS ._. An_DT
        increasing_VBG amount_NN of_IN data_NNS suggests_VBZ that_IN the_DT RAR-β_NNP isoform_NN ,_,
        which_WDT is_VBZ under_IN the_DT transcriptional_NN control_NN of_IN RAR-α_NNP ,_, is_VBZ
        involved_VBN in_IN suppressing_VBG cell_NN growth_NN and_CC tumorigenicity_NN [_NN
        11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ]_NN ._. Innovative_JJ molecules_NNS with_IN RAR-α_NNP
        and_CC RAR-β_NNP agonist_NN activity_NN could_MD therefore_RB present_VB more_RBR
        favorable_JJ toxicity_NN profile_NN than_IN pan-agonists_JJ ._.
        We_PRP applied_VBD a_DT flexible_JJ virtual_JJ screening_NN algorithm_NN
        (_( Molsoft_NNP ICM_NNP ,_, virtual_JJ library_NN screening_NN module_NN [_NN 17_CD ]_NN )_) which_WDT
        rapidly_RB docks_NNS hundreds_NNS of_IN thousands_NNS of_IN flexible_JJ compound_NN
        structures_NNS into_IN the_DT ligand_NN binding_JJ pocket_NN of_IN RAR_NNP ,_, and_CC
        discovered_VBD two_CD novel_NN RAR-β_NNP selective_JJ agonists_NNS ._. One_CD of_IN these_DT
        ligands_NNS displays_NNS original_JJ structural_JJ and_CC chemical_NN
        characteristics_NNS ,_, which_WDT could_MD be_VB used_VBN in_IN the_DT development_NN of_IN
        novel_NN compounds_NNS for_IN cancer_NN prevention_NN and_CC therapy_NN ._.
      
      
        Results_NNS and_CC discussion_NN
        We_PRP first_RB built_VBD a_DT model_NN of_IN the_DT RAR-α_NNP agonist_NN binding_JJ
        pocket_NN from_IN the_DT crystal_NN structure_NN of_IN the_DT RAR-γ_NNP ligand_NN
        binding_JJ domain_NN (_( RAR-γ_NNP LBD_NNP )_) /_NN all-trans_JJ RA_NNP complex_JJ [_NN 18_CD ]_NN ._.
        All_DT but_CC three_CD amino_JJ acids_NNS in_IN the_DT vicinity_NN of_IN the_DT ligand_NN are_VBP
        conserved_JJ between_IN the_DT two_CD isoforms_NNS ._. These_DT three_CD
        non-identical_JJ residues_NNS -_: A_DT 234_CD ,_, M_NNP 272_CD ,_, and_CC A_DT 397_CD -_: were_VBD changed_VBN
        to_TO the_DT RAR-α_NNP isoform_NN -_: S_NNP 234_CD ,_, I_PRP 272_CD and_CC V_NNP 397_CD -_: and_CC the_DT energy_NN
        of_IN the_DT system_NN was_VBD minimized_VBN (_( see_VB "_'' Materials_NNPS and_CC
        Methods_NNP "_'' )_) ._.
        In_IN order_NN to_TO address_VB the_DT accuracy_NN of_IN our_PRP$ model_NN of_IN the_DT
        RAR-α_NNP binding_JJ pocket_NN ,_, we_PRP docked_JJ Am_NNP 580_CD ,_, an_DT RAR-α_NNP specific_JJ
        agonist_NN [_NN 19_CD ]_NN ,_, into_IN the_DT receptor_NN (_( the_DT chemical_NN structure_NN of_IN
        Am_NNP 580_CD is_VBZ shown_VBN Fig_NNP ._. 1_LS b_SYM )_) ._. A_DT rapid_JJ docking_VBG procedure_NN with_IN
        flexible_JJ ligand_NN and_CC a_DT grid_NN representation_NN of_IN the_DT receptor_NN
        was_VBD followed_VBN by_IN an_DT extensive_JJ Monte_NNP Carlo_NNP energy_NN
        minimization_NN with_IN both_DT ligand_NN and_CC receptor_NN side_NN chains_NNS
        flexible_JJ (_( see_VB "_'' Materials_NNPS and_CC Methods_NNP "_'' for_IN details_NNS )_) ._. The_DT
        ligand_NN superimposed_VBN well_RB with_IN the_DT natural_JJ hormone_NN all-trans_JJ
        RA_NNP (_( Fig_NNP ._. 2_LS a_DT )_) ._. Interestingly_RB ,_, Am_NNP 580_CD does_VBZ not_RB seem_VB to_TO fit_VB in_IN
        the_DT receptor_NN binding_JJ site_NN :_: the_DT ketone_NN oxygen_NN of_IN the_DT ligand_NN
        sticks_VBZ out_IN of_IN the_DT binding_JJ pocket_NN ,_, due_JJ to_TO too_RB close_JJ
        proximity_NN of_IN residue_NN 234_CD (_( Fig_NNP ._. 2_LS b_SYM )_) ._. However_RB ,_, in_IN the_DT complex_NN
        with_IN RAR-α_NNP ,_, this_DT ketone_NN oxygen_NN shares_NNS an_DT hydrogen_NN atom_NN with_IN
        the_DT hydroxyl_NN group_NN of_IN serine_NN 234_CD ,_, and_CC forms_VBZ a_DT stabilizing_VBG
        hydrogen_NN bond_NN ,_, while_IN a_DT steric_JJ clash_NN occurs_VBZ in_IN the_DT other_JJ two_CD
        RAR_NNP isoforms_NNS ,_, where_WRB residue_NN 234_CD is_VBZ an_DT alanine_NN ._.
        Consequently_RB ,_, our_PRP$ model_NN provides_VBZ a_DT rational_JJ for_IN Am_NNP 580_CD
        isoform_NN specificity_NN ,_, suggesting_VBG that_IN it_PRP is_VBZ relevant_JJ and_CC
        could_MD be_VB used_VBN as_IN a_DT template_NN for_IN the_DT discovery_NN of_IN novel_NN
        RAR-α_NNP agonist_NN structures_NNS ._.
        A_DT high_JJ throughput_NN virtual_JJ screening_NN was_VBD carried_VBN out_IN on_IN
        the_DT Available_NNP Chemicals_NNPS Directory_NNP (_( MDL_NNP Information_NNP Systems_NNPS ,_,
        San_NNP Leandro_NNP ,_, CA_NNP )_) ,_, a_DT compound_NN structure_NN database_NN of_IN over_IN
        150_CD ,_, 000_CD molecules_NNS ._. Each_DT compound_NN was_VBD automatically_RB docked_JJ
        into_IN a_DT grid_NN representation_NN of_IN RAR-α_NNP ,_, as_RB previously_RB
        described_VBD for_IN Am_NNP 580_CD ,_, and_CC assigned_VBN a_DT score_NN according_VBG to_TO the_DT
        quality_NN of_IN the_DT fit_JJ [_NN 8_CD ,_, 17_CD ,_, 20_CD ]_NN ._. The_DT 5364_CD ligand_NN candidates_NNS
        which_WDT scored_VBD better_JJR (_( i_NNP ._. e_SYM ._. lower_JJR )_) than_IN -_: 32_CD kcal_NN /_NN mol_NN were_VBD
        preselected_JJ for_IN a_DT more_RBR refined_JJ energy_NN minimization_NN
        procedure_NN ,_, with_IN flexible_JJ receptor_NN side_NN chains_NNS ,_, and_CC the_DT
        energy_NN of_IN complexation_NN was_VBD predicted_VBN as_RB previously_RB
        described_VBD [_NN 21_CD ]_NN (_( see_VB "_'' Materials_NNPS and_CC Methods_NNP "_'' )_) ._. After_IN
        careful_JJ visual_JJ examination_NN of_IN the_DT 300_CD candidates_NNS displaying_VBG
        the_DT lowest_JJS predicted_VBN binding_JJ energy_NN ,_, 30_CD molecules_NNS were_VBD
        selected_VBN and_CC purchased_VBN to_TO be_VB experimentally_RB tested_VBN 
        in_IN vitro_NN ._.
        HeLa_NNP cells_NNS were_VBD separately_RB transfected_JJ with_IN either_DT of_IN
        the_DT three_CD wild_JJ type_NN hRAR_NN isoforms_NNS ,_, and_CC a_DT ΔMTV-IR-CAT_JJ
        reporter_NN gene_NN [_NN 22_CD ,_, 23_CD ]_NN ._. The_DT cells_NNS were_VBD incubated_JJ with_IN each_DT
        ligand_NN at_IN concentrations_NNS from_IN 50_CD nM_NN to_TO 20_CD μM_NN to_TO stimulate_VB
        CAT_NNP activity_NN ._. Possible_JJ toxicity_NN of_IN the_DT compounds_NNS was_VBD
        deduced_JJ from_IN the_DT amount_NN of_IN cellular_JJ protein_NN extract_NN after_IN 2_CD
        days_NNS of_IN incubation_NN ._. The_DT percentage_NN of_IN conversion_NN induced_VBN by_IN
        1_CD μM_NN all-trans_JJ RA_NNP (_( RARs_NNP )_) or_CC 1_CD μM_NN 9_CD -_: cis_NNS RA_NNP (_( RXR-β_NNP )_) was_VBD used_VBN
        as_IN a_DT positive_JJ control_NN to_TO determine_VB the_DT maximum_NN induction_NN ._.
        Fig_NNP ._. 3_LS shows_VBZ all-trans_JJ RA_NNP induced_VBD conversion_NN of_IN RAR-α_NNP as_IN a_DT
        function_NN of_IN acid_NN concentration_NN ._. RAR-β_NNP could_MD induce_VB 20_CD %_NN of_IN
        the_DT maximum_JJ CAT_NNP activity_NN when_WRB activated_VBN by_IN 50_CD nM_NN agonist_NN 
        1_CD (_( chemical_NN structure_NN shown_VBN Fig_NNP ._. 1_LS c_SYM )_) ,_,
        while_IN RAR-γ_NNP was_VBD only_RB 12_CD %_NN active_JJ and_CC RAR-α_NNP not_RB active_JJ at_IN all_DT
        under_IN the_DT same_JJ conditions_NNS (_( Fig_NNP ._. 4_LS )_) ._. At_IN 200_CD nM_NN of_IN agonist_NN 
        1_CD ,_, RAR-β_NNP was_VBD 50_CD %_NN active_JJ ,_, RAR-γ_NNP 25_CD %_NN and_CC
        RAR-α_NNP 5_CD %_NN active_JJ ._. Similarly_RB ,_, RAR-β_NNP could_MD induce_VB 22_CD %_NN of_IN the_DT
        maximum_JJ CAT_NNP activity_NN when_WRB activated_VBN by_IN 50_CD nM_NN agonist_NN 
        2_CD (_( chemical_NN structure_NN shown_VBN Fig_NNP ._. 1_LS d_SYM )_) ._.
        RAR-α_NNP and_CC RAR-γ_NNP were_VBD 10_CD %_NN and_CC 14_CD %_NN active_JJ at_IN the_DT same_JJ
        concentration_NN of_IN agonist_NN ,_, respectively_RB ._. At_IN 200_CD nM_NN of_IN
        agonist_NN 
        2_CD ,_, RAR-β_NNP displayed_VBD 48_CD %_NN of_IN its_PRP$ maximal_NN
        activity_NN ,_, RAR-α_NNP 40_CD %_NN and_CC RAR-γ_NNP 17_CD %_NN ._. At_IN 20_CD μM_NN ,_, agonist_NN 
        1_CD induced_VBN full_JJ activation_NN of_IN RAR-β_NNP and_CC
        RAR-γ_NNP ,_, and_CC 80_CD %_NN activation_NN of_IN RAR-α_NNP ,_, showing_VBG that_IN this_DT
        compound_NN is_VBZ a_DT full_JJ agonist_NN ._. Agonist_NNP 
        2_CD was_VBD toxic_JJ for_IN the_DT cells_NNS at_IN 20_CD μM_NN ,_, as_IN
        shown_VBN by_IN protein_NN content_NN of_IN cell_NN culture_NN dishes_NNS ,_, which_WDT is_VBZ
        why_WRB little_JJ transcriptional_NN activity_NN was_VBD observed_VBN at_IN this_DT
        concentration_NN ._. However_RB ,_, little_JJ or_CC no_DT toxicity_NN was_VBD observed_VBN
        at_IN 8_CD μM_NN ,_, a_DT concentration_NN at_IN which_WDT agonist_NN 
        2_CD induced_VBN about_IN 50_CD %_NN maximal_NN activity_NN of_IN
        RAR-α_NNP and_CC RAR-β_NNP ,_, and_CC 35_CD %_NN maximal_NN activity_NN of_IN RAR-γ_NNP ._. Agonist_NNP
        1_CD was_VBD not_RB toxic_JJ at_IN 20_CD μM_NN ._. Finally_RB ,_, RXR-β_NNP was_VBD activated_VBN only_RB
        weakly_RB by_IN both_DT agonists_NNS 
        1_CD and_CC 
        2_CD at_IN 2_CD μM_NN ,_, but_CC was_VBD significantly_RB
        activated_VBN by_IN agonist_NN 1_CD at_IN 20_CD μM_NN (_( Fig_NNP ._. 4_LS )_) ._. Comparison_NNP of_IN
        Figs_NNP ._. 3_LS and_CC 4_CD also_RB shows_VBZ that_IN at_IN 200_CD nM_NN of_IN agonists_NNS 
        1_CD and_CC 
        2_CD ,_, RAR-β_NNP exhibits_VBZ the_DT same_JJ activity_NN as_IN
        the_DT positive_JJ control_NN RAR-α_NNP induced_VBN by_IN all-trans_JJ RA_NNP at_IN the_DT
        same_JJ concentration_NN ._.
        The_DT predicted_VBN structure_NN of_IN the_DT complex_JJ generated_VBN by_IN the_DT
        virtual_JJ screening_NN approach_NN ,_, and_CC further_JJ optimized_JJ with_IN
        flexible_JJ receptor_NN side-chains_JJ details_NNS clearly_RB the_DT
        interactions_NNS between_IN the_DT receptor_NN and_CC the_DT ligands_NNS (_( Fig_NNP ._. 5_LS )_) ._.
        Agonist_NNP 
        1_CD and_CC 
        2_CD both_DT have_VBP a_DT carboxylate_NN group_NN which_WDT
        superimposes_NNS with_IN the_DT carboxylate_NN of_IN all-trans_JJ RA_NNP ,_, and_CC
        makes_VBZ stabilizing_VBG hydrogen_NN bonds_NNS with_IN Arg_NNP 274_CD and_CC 278_CD ,_, and_CC
        the_DT backbone_NN nitrogen_NN of_IN Ser_NNP 289_CD (_( Fig_NNP ._. 5_LS )_) ._. All_DT other_JJ
        receptor_NN /_NN ligand_NN interactions_NNS are_VBP hydrophobic_JJ ._. As_IN a_DT result_NN ,_,
        the_DT size_NN and_CC flexibility_NN of_IN the_DT ligand_NN as_RB well_RB as_IN the_DT shape_NN
        complementarity_NN with_IN the_DT receptor_NN are_VBP critical_JJ for_IN affinity_NN
        and_CC specificity_NN ._.
        The_DT structure_NN of_IN agonist_NN 
        2_CD is_VBZ almost_RB similar_JJ to_TO that_DT of_IN Ch_NNP 55_CD
        (_( Fig_NNP ._. 1_LS e_SYM )_) ,_, another_DT RAR-β_NNP selective_JJ agonist_NN [_NN 24_CD ]_NN with_IN 0_CD ._. 44_CD ,_,
        0_CD ._. 04_CD and_CC 1_CD ._. 7_CD nM_NN Kd_NNP for_IN RAR-α_NNP ,_, RAR-β_NNP and_CC RAR-γ_NNP respectively_RB
        [_NN 4_CD ]_NN ._. However_RB ,_, agonist_NN 
        2_CD has_VBZ an_DT additional_JJ hydroxyl_NN group_NN on_IN
        the_DT aromatic_JJ ring_NN ._. The_DT observation_NN that_IN Ch_NNP 55_CD displays_NNS some_DT
        potency_NN against_IN the_DT growth_NN of_IN human_JJ non-small_JJ cell_NN lung_NN
        carcinoma_NN cells_NNS [_NN 4_CD ]_NN as_RB well_RB as_IN anti-angiogenic_JJ activity_NN [_NN
        25_CD ]_NN suggests_VBZ that_DT agonist_NN 
        2_CD is_VBZ a_DT good_JJ lead_NN candidate_NN for_IN cancer_NN
        therapy_NN ._. Since_IN this_DT compound_NN was_VBD discovered_VBN through_IN a_DT
        single_JJ virtual_JJ library_NN screening_NN ,_, this_DT is_VBZ a_DT very_RB
        encouraging_VBG result_NN which_WDT also_RB constitutes_VBZ a_DT validation_NN of_IN
        our_PRP$ method_NN ._.
        The_DT structure_NN of_IN agonist_NN 
        1_CD is_VBZ entirely_RB novel_NN ;_: it_PRP is_VBZ the_DT first_JJ
        RAR_NNP ligand_NN described_VBD so_RB far_RB with_IN either_DT a_DT thiazole_NN ring_NN or_CC
        a_DT trifluoro_NN group_NN ._. It_PRP presents_VBZ a_DT very_RB limited_JJ level_NN of_IN
        flexibility_NN and_CC fits_VBZ tightly_RB into_IN the_DT receptor_NN 's_POS binding_JJ
        pocket_NN ._. This_DT compound_NN illustrates_VBZ the_DT benefits_NNS of_IN the_DT 
        in_IN silico_NN screening_NN procedure_NN ,_, a_DT
        rational_JJ approach_NN which_WDT is_VBZ based_VBN solely_RB on_IN the_DT structure_NN of_IN
        the_DT receptor_NN ,_, and_CC is_VBZ not_RB biased_VBN towards_IN existing_VBG ligands_NNS ._.
        Indeed_RB ,_, structure-based_JJ drug_NN design_NN usually_RB derives_VBZ novel_NN
        compound_NN structures_NNS from_IN ligands_NNS previously_RB described_VBD ._. Our_PRP$
        approach_NN enabled_VBD the_DT discovery_NN 
        ab_NN initio_NN of_IN RAR_NNP agonists_NNS displaying_VBG
        some_DT activity_NN at_IN 50_CD nM_NN with_IN a_DT 7_CD %_NN success_NN rate_NN ._.
        The_DT specificity_NN profile_NN of_IN the_DT two_CD RAR_NNP ligands_NNS described_VBD
        here_RB are_VBP similar_JJ to_TO that_DT of_IN Ch_NNP 55_CD ,_, a_DT compound_NN with_IN ten_CD times_NNS
        higher_JJR affinity_NN for_IN RAR-β_NNP than_IN RAR-α_NNP ,_, and_CC which_WDT can_MD block_VB
        the_DT growth_NN of_IN certain_JJ cancer_NN types_NNS [_NN 4_CD ]_NN ._. It_PRP will_MD be_VB
        interesting_JJ to_TO test_VB these_DT molecules_NNS for_IN anti-proliferative_JJ
        activity_NN ,_, both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN ._. The_DT observation_NN that_DT
        agonist_NN 
        1_CD does_VBZ not_RB belong_VB to_TO any_DT of_IN the_DT series_NN
        of_IN RAR_NNP ligands_NNS described_VBD so_RB far_RB makes_VBZ this_DT compound_NN
        particularly_RB interesting_JJ for_IN further_JJ development_NN ._.
        While_IN a_DT model_NN of_IN RAR-α_NNP was_VBD used_VBN to_TO conduct_VB the_DT virtual_JJ
        screening_NN ,_, agonists_NNS 
        1_CD and_CC 
        2_CD have_VBP an_DT EC-_NNP 50_CD of_IN 200_CD nM_NN for_IN RAR-β_NNP ,_,
        and_CC an_DT EC-_NNP 50_CD of_IN 4_CD and_CC 2_CD μM_NN respectively_RB for_IN RAR-α_NNP ._. This_DT
        observation_NN emphasizes_VBZ the_DT primary_JJ goal_NN of_IN structure-based_JJ
        screening_NN procedures_NNS ,_, which_WDT is_VBZ to_TO significantly_RB accelerate_VB
        the_DT initial_JJ steps_NNS of_IN lead_NN identification_NN projects_NNS by_IN
        automatically_RB discriminating_VBG between_IN binders_NNS and_CC
        non-binders_JJ ,_, rather_RB than_IN ranking_JJ ligands_NNS according_VBG to_TO their_PRP$
        affinity_NN for_IN the_DT receptor_NN ._. The_DT discovery_NN of_IN 2_CD RAR-α_NNP
        agonists_NNS out_IN of_IN 30_CD molecules_NNS tested_VBN is_VBZ a_DT good_JJ illustration_NN
        of_IN this_DT approach_NN ._.
      
      
        Conclusions_NNP
        This_DT report_NN details_NNS the_DT rapid_JJ discovery_NN of_IN RAR_NNP agonists_NNS
        with_IN novel_NN structural_JJ features_NNS ,_, thanks_NNS to_TO a_DT powerful_JJ
        virtual_JJ ligand_NN screening_NN approach_NN ,_, and_CC a_DT research_NN strategy_NN
        where_WRB considerations_NNS on_IN existing_VBG ligands_NNS are_VBP avoided_VBN ._. One_CD
        of_IN the_DT molecules_NNS presented_VBN here_RB constitute_VBP a_DT good_JJ framework_NN
        for_IN the_DT development_NN of_IN a_DT novel_NN series_NN of_IN RAR_NNP ligands_NNS very_RB
        different_JJ from_IN all_DT structures_NNS described_VBD so_RB far_RB ._. Such_JJ
        ligands_NNS could_MD present_VB more_RBR favorable_JJ specificity_NN and_CC
        toxicity_NN profiles_NNS ,_, and_CC have_VBP important_JJ applications_NNS in_IN
        cancer_NN therapy_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Modeling_NNP of_IN RAR-alpha_NNP ligand_NN binding_JJ pocket_NN
          The_DT crystal_NN structure_NN of_IN RAR-γ-LBD_NNP complexed_JJ to_TO
          all-trans_JJ RA_NNP was_VBD used_VBN as_IN a_DT template_NN [_NN 18_CD ]_NN and_CC the_DT three_CD
          residues_NNS in_IN the_DT vicinity_NN of_IN the_DT ligand_NN which_WDT are_VBP not_RB
          conserved_JJ between_IN the_DT two_CD isoforms_NNS were_VBD modified_VBN
          accordingly_RB :_: A_DT 234_CD ,_, M_NNP 272_CD ,_, and_CC A_DT 397_CD were_VBD changed_VBN to_TO S_NNP 234_CD ,_,
          I_PRP 272_CD and_CC V_NNP 397_CD respectively_RB ._. The_DT rotation_NN variables_NNS of_IN the_DT
          side_NN chains_NNS within_IN 3_CD ._. 5_CD Å_NN of_IN the_DT modified_VBN residues_NNS were_VBD
          unfixed_JJ and_CC the_DT energy_NN of_IN the_DT system_NN was_VBD minimized_VBN in_IN the_DT
          internal_JJ coordinate_VB space_NN ,_, according_VBG to_TO the_DT ICM_NNP method_NN [_NN
          26_CD ,_, 29_CD ]_NN ._.
        
        
          Docking_NNP of_IN AM_NNP 580_CD into_IN RAR-alpha_NNP
          The_DT flexible_JJ ligand_NN was_VBD docked_JJ into_IN a_DT combination_NN of_IN
          five_CD potential_JJ map_NN representations_NNS of_IN the_DT RAR-α_NNP ligand_NN
          binding_JJ pocket_NN ,_, which_WDT account_VBP for_IN two_CD Van_NNP der_NNP Waals_NNP
          boundaries_NNS ,_, hydrophobicity_NN ,_, electrostatics_NNS and_CC hydrogen_NN
          bonding_NN profiles_NNS [_NN 20_CD ,_, 27_CD ]_NN ._. This_DT rapid_JJ docking_VBG procedure_NN
          was_VBD followed_VBN by_IN a_DT more_RBR refined_JJ energy_NN minimization_NN of_IN the_DT
          complex_NN ,_, with_IN a_DT full_JJ atom_NN representation_NN of_IN the_DT receptor_NN ,_,
          and_CC flexible_JJ receptor_NN side_NN chains_NNS ,_, according_VBG to_TO the_DT ICM_NNP
          stochastic_JJ global_JJ optimization_NN algorithm_NN [_NN 26_CD ,_, 27_CD ]_NN as_IN
          implemented_VBN in_IN the_DT Molsoft_NNP ICM_NNP 2_CD ._. 7_CD program_NN [_NN 17_CD ]_NN ._.
        
        
          Virtual_NNP screening_NN of_IN the_DT compound_NN structure_NN
          database_NN
          The_DT ICM_NNP program_NN [_NN 17_CD ]_NN was_VBD used_VBN to_TO perform_VB both_DT
          receptor_NN modeling_NN and_CC virtual_JJ ligand_NN screening_NN ._. The_DT
          procedure_NN followed_VBN was_VBD similar_JJ than_IN previously_RB described_VBD
          [_NN 8_CD ]_NN :_: each_DT flexible_JJ ligand_NN of_IN the_DT Available_NNP Chemicals_NNPS
          Directory_NNP (_( MDL_NNP Information_NNP Systems_NNPS ,_, San_NNP Leandro_NNP )_) was_VBD
          docked_JJ automatically_RB into_IN the_DT combination_NN of_IN potential_JJ
          maps_NNS described_VBD above_IN ,_, and_CC assigned_VBN a_DT score_NN according_VBG to_TO
          its_PRP$ fit_NN with_IN the_DT receptor_NN ._. The_DT scoring_VBG function_NN included_VBD
          continuum_NN as_RB well_RB as_IN discreet_JJ electrostatics_NNS ,_,
          hydrophobicity_NN and_CC entropy_NN parameters_NNS [_NN 20_CD ]_NN ._. The_DT
          screening_NN of_IN the_DT database_NN of_IN over_IN 150_CD ,_, 000_CD ligands_NNS took_VBD
          less_JJR than_IN a_DT month_NN on_IN 10_CD "_'' 194_CD MHZ_NNP IP_NNP 25_CD "_'' processors_NNS ._. Using_VBG
          the_DT same_JJ computing_NN power_NN ,_, the_DT 5364_CD compounds_NNS which_WDT scored_VBD
          better_JJR (_( i_NNP ._. e_SYM ._. lower_JJR )_) than_IN -_: 32_CD were_VBD preselected_JJ for_IN a_DT
          second_JJ automatic_JJ round_NN of_IN selection_NN :_: they_PRP were_VBD all_DT docked_JJ
          in_IN two_CD days_NNS into_IN a_DT full_JJ atom_NN representation_NN of_IN the_DT
          receptor_NN ,_, with_IN flexible_JJ receptor_NN side_NN chains_NNS ,_, according_VBG
          to_TO a_DT global_JJ energy_NN optimization_NN in_IN internal_JJ coordinates_VBZ [_NN
          17_CD ,_, 26_CD ,_, 27_CD ,_, 28_CD ]_NN ._. The_DT structure_NN generated_VBN by_IN the_DT initial_JJ
          library_NN screening_NN was_VBD used_VBN as_IN a_DT starting_NN point_NN for_IN this_DT
          second_NN ,_, more_RBR refined_JJ ,_, docking_VBG procedure_NN ._. The_DT binding_JJ
          energy_NN of_IN the_DT compounds_NNS was_VBD then_RB evaluated_VBN with_IN a_DT
          boundary_NN elements_NNS implementation_NN of_IN solvation_NN
          electrostatics_NNS [_NN 21_CD ]_NN and_CC the_DT 300_CD compounds_NNS showing_VBG the_DT
          lowest_JJS binding_JJ energy_NN were_VBD selected_VBN for_IN further_JJ
          examination_NN ._. After_IN careful_JJ visual_JJ inspection_NN for_IN shape_NN
          complementarity_NN ,_, hydrogen_NN bonding_NN network_NN ,_, compound_NN
          flexibility_NN ,_, and_CC potential_JJ Van_NNP der_NNP Waals_NNP clashes_NNS ,_, 30_CD
          molecules_NNS out_IN of_IN 300_CD were_VBD selected_VBN and_CC purchased_VBN to_TO be_VB
          experimentally_RB tested_VBN 
          in_IN vitro_NN ._. We_PRP should_MD stress_VB out_IN
          here_RB that_IN the_DT Van_NNP der_NNP Waals_NNP term_NN is_VBZ too_RB noisy_NN to_TO be_VB added_VBN
          to_TO the_DT binding_JJ energy_NN function_NN ,_, as_IN discussed_VBN in_IN details_NNS
          elsewhere_RB [_NN 21_CD ]_NN ._. As_IN a_DT consequence_NN ,_, some_DT compounds_NNS with_IN a_DT
          low_RB predicted_VBD binding_JJ energy_NN were_VBD not_RB retained_VBN ,_, because_IN
          they_PRP seemed_VBD likely_JJ to_TO clash_VB sterically_RB with_IN the_DT
          receptor_NN ._.
        
        
          Biological_JJ activity_NN of_IN the_DT ligand_NN candidates_NNS
          HeLa_NNP cells_NNS were_VBD transfected_JJ by_IN calcium_NN phosphate_NN
          precipitation_NN using_VBG 1_CD μg_NN of_IN plasmid_NN expressing_VBG the_DT full_JJ
          length_NN receptor_NN isoform_NN and_CC 1_CD μg_NN of_IN a_DT ΔMTV-IR-CAT_JJ
          reporter_NN gene_NN ,_, as_RB previously_RB described_VBD [_NN 22_CD ,_, 23_CD ]_NN ._. Ligands_NNP
          were_VBD dissolved_VBN in_IN DMSO_NNP at_IN 20_CD mM_NN final_JJ concentration_NN ._. Cell_NNP
          cultures_NNS were_VBD supplemented_JJ with_IN indicated_VBD ligands_NNS
          immediately_RB after_IN addition_NN of_IN the_DT calcium_NN phosphate_NN /_NN DNA_NNP
          precipitate_NN ._. Media_NNP and_CC ligands_NNS were_VBD replaced_VBN after_IN 24_CD h_NN
          and_CC cells_NNS were_VBD harvested_VBN and_CC assayed_JJ for_IN CAT_NNP activity_NN 24_CD
          h_NN later_RB :_: acetylated_JJ and_CC unreacted_JJ [_NN 14_CD C_NNP ]_NN chloramphenicol_NN
          was_VBD excised_VBN from_IN a_DT thin_JJ layer_NN chromatography_NN plate_NN and_CC
          quantitated_JJ in_IN a_DT liquid_JJ scintillation_NN counter_NN ._. The_DT amount_NN
          of_IN cellular_JJ protein_NN extract_NN after_IN two_CD days_NNS of_IN incubation_NN
          was_VBD measured_VBN to_TO determine_VB the_DT compounds_NNS toxicity_NN ._. Agonist_NNP
          1_CD was_VBD purchased_VBN from_IN Bionet_NNP Research_NNP (_( catalog_NN number_NN
          1_CD G-_NNP 433_CD S_NNP )_) ._. Agonist_NNP 2_CD was_VBD purchased_VBN from_IN Sigma-_NNP Aldrich_NNP
          (_( Sigma_NNP Aldrich_NNP library_NN of_IN rare_JJ chemicals_NNS ._. Catalog_NN number_NN
          S_NNP 08503_CD -_: 1_LS )_) ._.
        
      
    
  
